ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
CBD, also known as cannabidiol, is one of the most important healing substances in the hemp plant, helping treat inflammation, convulsions, insomnia, anxiety, ulcers, neuropathic pain, and epilepsy, among other medical problems. The difference between CBD and THC is that THC is classified as a federally controlled psychotropic drug, whereas CBD is recognized as not only safe but legal.
In an article entitled ‘Can Cannabis Oil Treat Seizures?’ by ConsumerReports.org (http://dtn.fm/Pab9w), results from clinical studies in which doctors treated patients suffering from seizures with CBD showed that Cannabidiol reduced seizures by a monthly average of 36.5%, five patients no longer had motor seizures, and two patients’ seizures completely stopped.
Despite this, the evidence was deemed insufficient as there was not enough to make a solid case, the studies did not include placebo controls, and certain patients stated that they were taking other anti-epilepsy drugs during the clinical trials. However, although these particular trials were not deemed sufficient to prove CBD could potentially treat epileptic seizures, scientists have growing enthusiasm for the use of cannabidiol as a treatment.
There are now several pharmaceutical companies conducting clinical trials of CBD-based drugs, according to The Pharmaceuticals Journal (http://dtn.fm/hu3sT). These trials will offer guidance on dosage, efficacy, concerns regarding side effects, and the safety of CBD as a form of treatment. With this in mind, ChineseInvestors.com recently launched its own ChineseCBDOil.com website, with the aim of selling CBD oil products to not only clients in the U.S., but also to those on the Chinese mainland.
Although the use of cannabis is not legal in China, CBD is. As a result, the company is acting as a first mover in the market, soon to be offering its own consumer application that will offer Chinese-speaking consumers location-based information about where to buy the products in question. The company plans to acquire formal government approval for its CBD oil-based pharmaceutical to treat epilepsy in the next two to four years.
For more information, visit the company’s website at www.ChineseInvestors.com